About 1 in 5 patients with B-cell lymphoma treated with loncastuximab develop skin-related adverse events, particularly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results